Loading
A phase 3 trial of Durvalumab and Osimertinib in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation is a phase 3 interventional study registered as NCT03833154 by AstraZeneca, with 724 participants enrolled, started 2019-03-06 and due to reach its primary completion in 2028-10-31. Interventions recorded: Durvalumab and (Osimertinib cohort, single-arm, open-label separate cohort).
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Small-molecule kinase inhibitors, Immune checkpoint inhibitors and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.